Navigation Links
Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
Date:10/24/2007

- favorable pharmacokinetic and safety data observed in first clinical

trial of novel Fleximer(TM) anticancer agent -

CAMBRIDGE, Mass., Oct. 24 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced interim results of a Phase I study of its lead product candidate, XMT-1001, in patients with advanced solid tumors. The data was presented by Edward A. Sausville, M.D., Ph.D, Professor of Medicine and Associate Director for Clinical Research, University of Maryland Greenebaum Cancer Center in a poster session on October 23 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics taking place in San Francisco, CA. Full text of the abstract #A146 "A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients with Advanced Solid Tumors" can be viewed online at the AACR website at http://www.aacr.org. XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity.

Commenting on the data, Robert J. Fram, M.D. Chief Medical Officer at Mersana, stated: "The Phase I results show that, in humans, camptothecin, the active agent in XMT-1001, is released gradually from the Fleximer carrier as a pro-drug in a manner that will potentially avoid common safety problems associated with drugs in this class. To date, we've seen no evidence of drug-related serious adverse events and the study is ongoing."

Results were presented from 12 patients enrolled in an ongoing Phase I open-label, dose-escalation trial designed to determine the safety, tolerability and pharmacokinetic profile of XMT-1001. To date, XMT-1001 has been well tolerated in patients and no serious drug related adverse events have been reported. Preliminary results demonstrate a favorable pharmacokinetic profile with low levels of CPT, both total and free, recovered in urine. The ma
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014   Decision Resources Group finds that ... chronic kidney disease non-dialysis (CKD-ND) patients are not ... In addition, one-year persistency is similar between Amgen,s ... key findings from the report entitled ... Stimulating Agents in Late Stage Chronic Kidney Disease ...
(Date:9/30/2014)... Ind. , Sept. 30, 2014  The orthopedic specialists ... the nation,s No. 6 orthopedic group by US News ... Active Adults," a series of free, public seminars to ... all over the world come to see the knee ... procedures are now available at Munster Specialty Surgery Center. ...
(Date:9/30/2014)... In 2011, approximately 5.1 million people in ... pain relievers (e.g. opioids). 1 Clinical treatments for ... the use of buprenorphine, buprenorphine/naloxone, naltrexone or methadone. The ... developing and improving care management programs, according to ... Therapeutics LLC (Prime). Cost trends ...
Breaking Medicine Technology:Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
... , LITTLE FALLS, N.J., Dec. 2 ... the results for its first quarter ended October 31, 2009 on ... to discuss the results at 11:00 AM ET. Participating in ... President and CEO; Seth R. Segel, Executive Vice President; Craig A. ...
... , , CENTENNIAL, Colo., Dec. 2 ... bone and soft tissue allografts for use in surgical procedures ... substitutes, today announced its sponsorship of a truly iconic symbol ... Life float in the January 1, 2010 Tournament of Roses ...
Cached Medicine Technology:Cantel Medical Corp. to Hold Conference Call to Discuss Results for its First Quarter Ended October 31, 2009 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 3
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... released by Blue Star Nutraceuticals designed to help maximize ... ingredients that optimizes the body’s absorption of glucose has ... review. , “The main purpose behind Glycodrive is ... that builds lean muscle,” reports Michaels. “Carbs are essential ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... plastic surgery providers in Turkey has gone up more ... of growth. The medical tourism company also reported total ... since October 2012. , The company’s professional strategy has ... in Turkey — ultimately designed for patient comfort and ...
(Date:9/30/2014)... Washington, DC (PRWEB) September 30, 2014 A ... the world to combat an epidemic that, left unchecked, could ... no, they are not headed to Africa. John Rogers, the ... headed to North Korea to fight a disease most think ... the US some 80 years ago is on the comeback ...
(Date:9/30/2014)... 2014) Levothyroxine is considered the gold standard therapy ... review of therapies for the condition including combining ... assessment, say a team of investigators.,1Their analysis, published as ... , finds insufficient consistent data exist to recommend a ... sold under various trade names, such as Synthroid ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2
... EDITOR,S PICK: At-TRIB(1)-uting a gene a new function in the ... region of human chromosome 8 have recently been linked to ... risk of atherosclerosis (a disease of the major arterial blood ... stroke). The only currently described gene in this region of ...
... the primary care team right in doctors, offices may ... manage associated risks, a new University of Alberta study ... Type 2 diabetes dropped significantly when pharmacists were included ... U of A study showed. Among 153 patients whose ...
... -- People who started smoking marijuana at a young age ... those who started smoking when they were older, a new ... marijuana and the need to develop effective strategies to reduce ... noted that adolescence is a critical time in brain development. ...
... (HealthDay News) -- People who wear multifocal contact lenses have ... a new study finds. Multifocal lenses correct near vision ... This study included 11 volunteers, aged 45 to 64, ... Wearing multifocal contact lenses resulted in significantly slower ...
... � Following the Plenary Session of the 2010 ... (PSWC) in association with the American Association of ... Danny D. Shen, Ph.D. presented the following ground-breaking ... pharmaceutical sciences: AAPS Presidential Citation , ...
... procedure, using a robotic arm alongside 3-D mapping, is due ... It comes six months after Dr Andre Ng carried out ... Robotic Catheter System. Dr Ng, is senior lecturer ... at Glenfield Hospital. On Tuesday 16 November, Dr ...
Cached Medicine News:Health News:JCI online early table of contents: Nov. 15, 2010 2Health News:JCI online early table of contents: Nov. 15, 2010 3Health News:JCI online early table of contents: Nov. 15, 2010 4Health News:JCI online early table of contents: Nov. 15, 2010 5Health News:JCI online early table of contents: Nov. 15, 2010 6Health News:Early 'Pot' Use May Harm Brain More: Study 2Health News:AAPS presents awards to exemplary researchers 2Health News:AAPS presents awards to exemplary researchers 3Health News:AAPS presents awards to exemplary researchers 4Health News:Robo-op marks new world first for heart procedure 2
The fat loss formula's key ingredient of 2.0% aminophylline works by penetrating deep into the skin where it causes the body fat cells to shrink, resulting in up to 2 inches of body fat loss....
... VelaSmooth is the first ... device with the revolutionary elos ... Radio Frequency and Infrared Light ... with suction to reduce the ...
... was designed with the physician, staff ... you the best economy exam room ... does not skimp on patient comfort. ... can easily position patients so that ...
The Salt A-Peel™ microdermabrasion combines, positive air pressure, pure salt, ultrasound and the application of rich anti oxidant products to deliver a remarkable 'The Salt A-Peel' anti ageing...
Medicine Products: